A Prat

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
  2. doi Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 20:294-7. 2009
  3. ncbi Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    E Felip
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 18:ix143-6. 2007
  4. doi Contacts with children and young people and adult risk of suffering herpes zoster
    M Salleras
    Dermatology Department, Sagrado Corazón Hospital, Barcelona, Spain
    Vaccine 29:7602-5. 2011
  5. doi [Institute for clinical management of nephro-urological diseases: the benefits of a quality care programme]
    M Santiñá
    Dirección de Calidad y Seguridad Clínica, Hospital Clinic de Barcelona, Barcelona, Spain
    Nefrologia 29:118-22. 2009
  6. ncbi Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study
    L Salleras
    Preventive Medicine Unit, Department of Public Health, School of Medicine, University of Barcelona, Casanova 143, Barcelona, Spain
    Vaccine 24:6638-42. 2006
  7. ncbi Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives
    E Navas
    Department of Health, Autonomous Government of Catalonia Spain, Travessera de les Corts, 131 59, 08028 Barcelona, Spain
    Vaccine 25:3233-9. 2007
  8. ncbi Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)
    E Navas
    General Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131 159, 08028 Barcelona, Spain
    Vaccine 23:2342-8. 2005
  9. ncbi Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools
    E Navas
    General Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131 159, 08028 Barcelona, Spain
    Vaccine 23:2185-9. 2005
  10. ncbi Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions
    A M Khatib
    Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec H2W 1R7, Canada
    J Biol Chem 276:30686-93. 2001

Collaborators

Detail Information

Publications10

  1. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
    ..The aim of this retrospective study is to analyze the prognostic value of the CA-125 nadir after the completion of an optimal primary treatment...
  2. doi Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 20:294-7. 2009
    ..In addition, we tested the new proposed early CA-125 signal of progressive disease (EPD) criterion in the same study population...
  3. ncbi Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    E Felip
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 18:ix143-6. 2007
  4. doi Contacts with children and young people and adult risk of suffering herpes zoster
    M Salleras
    Dermatology Department, Sagrado Corazón Hospital, Barcelona, Spain
    Vaccine 29:7602-5. 2011
    ..56 [0.37-0.85]). Herpes-zoster vaccination in immunocompetent people aged ≥ 50 years could counteract the possible negative effects of mass varicella vaccination in childhood on the epidemiology of herpes zoster in adults...
  5. doi [Institute for clinical management of nephro-urological diseases: the benefits of a quality care programme]
    M Santiñá
    Dirección de Calidad y Seguridad Clínica, Hospital Clinic de Barcelona, Barcelona, Spain
    Nefrologia 29:118-22. 2009
    ....
  6. ncbi Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study
    L Salleras
    Preventive Medicine Unit, Department of Public Health, School of Medicine, University of Barcelona, Casanova 143, Barcelona, Spain
    Vaccine 24:6638-42. 2006
    ..Vaccination of children aged 3-14 years in pediatric practices with one dose of virosomal subunit inactivated influenza vaccine has the potential to considerably reduce the health and social burdens caused by influenza-related illnesses...
  7. ncbi Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives
    E Navas
    Department of Health, Autonomous Government of Catalonia Spain, Travessera de les Corts, 131 59, 08028 Barcelona, Spain
    Vaccine 25:3233-9. 2007
    ....
  8. ncbi Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)
    E Navas
    General Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131 159, 08028 Barcelona, Spain
    Vaccine 23:2342-8. 2005
    ..The benefit-cost ratio was 0.59 euros from the societal perspective. The cost per disability adjusted life year (DALY) gained was 44,307 euros from the societal perspective and 80,291 euros from the provider's perspective...
  9. ncbi Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools
    E Navas
    General Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131 159, 08028 Barcelona, Spain
    Vaccine 23:2185-9. 2005
    ..98) the net present value of the programme was positive (+533,708) and the benefit-cost ratio was 2.58. If the estimated disease incidence were reduced by half, the programme would still be efficient...
  10. ncbi Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions
    A M Khatib
    Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec H2W 1R7, Canada
    J Biol Chem 276:30686-93. 2001
    ..These findings indicate that PCs actively contribute to the growth and malignant phenotypes of HT-29 tumors, suggesting that PC inhibition strategies may be a useful adduct to the arsenal of colorectal anticancer gene therapies...